A Part of the University of Maryland Medical Center

Connect with UMGCC
Facebook Twitter YouTube Blog iPhone
Email PageEmail page Print PagePrint page

Research Programs

News Briefs

Events, Lectures, and Workshops:

More than 40 members of the University of Maryland Greenebaum Cancer Center’s Hematologic Malignancies team, including faculty, fellows, residents, and staff, served as presenters, authors or moderators for more than 50 scientific and educational sessions at the annual American Society for Hematology (ASH) meeting held in Atlanta from December 8-11, 2012.

The University of Maryland Greenebaum Cancer Center (UMGCC) has been named a Center of Excellence for the treatment of myelodysplastic syndromes by the Myelodysplastic Syndromes (MDS) Foundation. The center of excellence designation recognizes academic cancer centers that have particular expertise in treating patients with MDS, have available cytogenetics and/or molecular genetics resources, have published peer-reviewed publications in the field and offer patients access to clinical research trials investigating new approaches to the prevention, diagnosis and treatment MDS.

New Grant Awards:

Amy Fulton, Ph.D., Professor, Department of Pathology and a member of the Greenebaum Cancer Center, received a one-year CRF Pilot grant award of $75,000 entitled “Prostaglandin E Receptor EP4 as a Novel Therapeutic Target in Malignancy” on November 1, 2012.

Maria Baer, M.D., Professor, Department of Medicine and a member of the Greenebaum Cancer Center, received a one-year CRF Pilot grant award of $62,500 entitled “Targeting Cellular Redox Pathways to Overcome Chemotherapy Resistance in Acute Myeloid Leukemia” on January 1, 2012.

Eduardo Davila, Ph.D., Assistant Professor, Department of Head and Neck Surgery and a member of the Greenebaum Cancer Center, in collaboration with Dr. Sue Ostrand- Rosenberg (UMBC) received a one-year CRF Pilot grant award of $75,000 titled “Redirecting T Cells to Simultaneously Eliminate Tumor and Neutralize Immune Suppression” on November 1, 2102.

Robert Gallo, M.D. and William Blattner, M.D., Professors, Institute for Human Virology and members of the Greenebaum Cancer Center, received a one-year CRF Pilot grant award of $75,000 entitled “Pathogenic Role of HIV-1 p17 Variants in AIDS Associated Lymphomas” on November 1, 2012.

Curt Civin, M.D., Professor, Department of Pediatrics and Physiology, Associate Dean for Research, School of Medicine, Director, Center for Stem Cell Biology & Regenerative Medicine and a member of the Greenebaum Cancer Center, received a one-year CRF Pilot grant award of $62,500 entitled “Interplay of miR-34, S100, and Artemesinins in Leukemias and Melanomas” on January 1, 2012.

Fey Rassool, Ph.D., Department of Radiation Oncology and a member of the Greenebaum Cancer Center, received a one-year “Stand Up to Cancer” Inaugural Laura Ziskin Prize in Translation Cancer Research Award of $125,000 for entitled “Breast Cancer Research Linking Epigenetics to DNA Repair Mechanisms” on November 1, 2012.

Ronald Gartenhaus, M.D., Professor, Department of Medicine and a member of the Greenebaum Cancer Center, and Andy Evans, M.D., at the University of Massachusetts are co-PIs on a five-year National Cancer Institute R01 grant of $1,250,000 entitled “MAP Kinase Signaling in Lymphoma: A Novel Therapeutic Paradigm.”

Stuart Martin, Ph.D., Associate Professor, Department of Physiology and a member of the Greenebaum Cancer Center, received a new, five-year R01 from the National Cancer Institute for $1.55 million entitled “Targeting microtubule stabilization to reduce breast tumor metastasis.”

Geoffrey Girnun, Ph.,D., Assistant Professor, Department of Biochemistry and Molecular Biology and a member of the Greenebaum Cancer Center, received a five-year R01 grant from the National Cancer Institute for $1,625,635 entitled “Metabolic Control of Hepatocellular Carcinoma by PGC1alpha.”


This page was last updated on: December 20, 2012.